This segment focuses on the research and development of therapies for pulmonary fibrosis, a chronic and progressive lung disease. Research and development activities include identifying and validating therapeutic targets, conducting preclinical studies, and designing and executing clinical trials. The company utilizes various technologies and methodologies, including stem cell stimulation and regenerative medicine approaches, to develop effective treatments. The primary therapeutic area is pulmonary fibrosis, with the goal of improving lung function and quality of life for patients. Market positioning involves targeting unmet medical needs in the pulmonary fibrosis space, with a focus on innovative therapies. Future opportunities include expanding the pipeline with additional drug candidates and exploring partnerships to accelerate clinical development and commercialization. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations are essential for accessing specialized expertise and resources, such as the strategic partnership with Azopharma.

This segment is dedicated to developing therapies to combat influenza infections. Research and development efforts include identifying antiviral compounds, conducting preclinical studies to assess efficacy and safety, and designing clinical trials to evaluate the effectiveness of potential treatments. The company leverages its expertise in immune system stimulation and anti-infective activity to develop innovative solutions. The primary therapeutic area is influenza infection, with the aim of reducing the severity and duration of the illness. Market positioning involves addressing the need for more effective and accessible influenza treatments. Future opportunities include expanding the product pipeline and exploring collaborations to accelerate clinical development and commercialization. Regulatory and clinical aspects involve obtaining necessary approvals from regulatory bodies and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations are crucial for accessing specialized expertise and resources, such as those related to vaccine adjuvancy.

This segment focuses on developing therapies to address radiation-induced neutropenia, a condition characterized by a decrease in the number of neutrophils, a type of white blood cell, often caused by radiation exposure. Research and development activities include identifying and validating therapeutic targets, conducting preclinical studies, and designing and executing clinical trials. The company utilizes technologies and methodologies focused on stem cell stimulation and immune system enhancement to develop effective treatments. The primary therapeutic area is radiation-induced neutropenia, with the goal of improving patient outcomes and reducing the risk of infection. Market positioning involves addressing the unmet medical needs of patients undergoing radiation therapy. Future opportunities include expanding the product pipeline and exploring collaborations to accelerate clinical development and commercialization. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations are essential for accessing specialized expertise and resources.

This segment focuses on the development of products and therapies for wound healing and regenerative medicine applications. Research and development activities include identifying and validating therapeutic targets, conducting preclinical studies, and designing and executing clinical trials. The company utilizes technologies and methodologies focused on stem cell stimulation, regenerative medicine, and biomaterials to develop effective treatments. The primary therapeutic area is wound healing, with the goal of accelerating the healing process and improving patient outcomes. Market positioning involves addressing the unmet medical needs of patients with chronic wounds and other related conditions. Future opportunities include expanding the product pipeline and exploring collaborations to accelerate clinical development and commercialization. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations are essential for accessing specialized expertise and resources, such as those related to biomaterial science and regenerative medicine.